Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy.

ABSTRACT:

Background

Cisplatin is an effective chemotherapeutic drug for treating various cancers including non-small cell lung cancer (NSCLC), but resistance to cisplatin remains the main limitation to its use in clinic. Astragaloside IV (AS-IV), which is derived from Astragalus membranaceus, has been proven to participate in various anti-cancer activities including anti-cancer, anti-oxidative, and anti-inflammatory functions.

Method

In this study, we explored the role of AS-IV in cisplatin chemoresistance to NSCLC cells by establishing cisplatin-resistant the NSCLC cell lines, A549^Cis and H1299^Cis.

Results

Cisplatin inhibited viability and promoted apoptosis of A549^Cis and H1299^Cis cells in a dose-dependent manner. In additio

SUBMITTER: Lai ST 

PROVIDER: S-EPMC7399439 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature